Maraviroc Intensification and Peripheral Blood Monocyte HIV DNA Levels

Inclusion Criteria: * HIV-1 infection as documented by ELISA and confirmed by either Western blot, HIV-1 culture, HIV-1 antigen, plasma HIV-1 RNA by RT-PCR or bDNA at any time prior to study entry. * Receipt of ARV medication uninterrupted for \> 1 year leading up to the screening period with demonstrated HIV RNA \< 50 copies/ml for a period of 1 year." * Willingness for both males and females of childbearing potential to utilize 2 effective contraception methods (2 separate forms, one of which must be an effective barrier method), be non-heterosexually active or have a an exclusive vasectomized partner from screening throughout the duration of the study treatment and for 30 days following the last dose of study drugs. * Age \>18 years. * Ability and willingness to provide written informed consent * The following laboratory parameters documented within 30 days prior to study entry: * Hemoglobin \>8.0 * Absolute neutrophil count \>500 * Platelet count \>40,000 * AST (SGOT) and ALT (SGPT) \<5 x ULN * Creatinine \<1.5 x ULN * Lipase \<2.0 x ULN * Estimated creatinine clearance \> 60 mL/min. * HIV DNA within peripheral blood mononuclear cells \> 100 copies/mL * Not currently receiving Maraviroc as part of ARV regimen Exclusion Criteria: * Past or present HIV opportunistic infection of the brain, learning disability, head injury with prolonged loss of consciousness or cognitive sequelae, or other non-HIV risk factor that may impact cognitive performance. * Any factor that precludes MRI scan including presence of metal or exposure to metal work (e.g., metal grinder/worker) and claustrophobia * History of seizure disorder * History of myocardial infarction, angina, congestive heart failure, peripheral vascular disease, angioplasty or cardiac surgery * Current malignancy or history of past malignancies excluding basal cell CA * Any immunomodulator, HIV vaccine, or investigational therapy within 30 days of study entry. * Any vaccination within 30 days of study entry. * Requirement for acute therapy for other AIDS-defining illness or other serious medical illnesses (in the opinion of the site investigator) within 14 days prior to study entry. * Other chronic illnesses including diabetes, autoimmune diseases, and endocrinopathies, except subjects on stable physiologic replacement therapy for low testosterone or thyroid levels * Known hypersensitivity to Maraviroc * Any condition which, in the opinion of the investigator, would compromise the subject's ability to participate in the study * Current active substance or alcohol dependence * Pregnancy or breast-feeding, intent to become pregnant during the course of the study.